OraSure Technologies, Inc. (NASDAQ:OSUR) was the target of unusually large options trading activity on Wednesday. Stock traders acquired 3,188 call options on the stock. This is an increase of 1,228% compared to the average volume of 240 call options.

OSUR has been the topic of several analyst reports. Zacks Investment Research raised shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a research report on Saturday, September 9th. Jefferies Group LLC reissued a “buy” rating and issued a $20.00 target price on shares of OraSure Technologies in a research report on Tuesday, September 12th. Canaccord Genuity reissued a “buy” rating and issued a $22.00 target price on shares of OraSure Technologies in a research report on Tuesday, September 19th. Finally, ValuEngine downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. OraSure Technologies currently has a consensus rating of “Buy” and an average price target of $18.21.

In other news, CEO Douglas A. Michels sold 22,923 shares of OraSure Technologies stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $23.00, for a total value of $527,229.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Mara G. Aspinall bought 5,000 shares of the company’s stock in a transaction dated Tuesday, November 7th. The stock was purchased at an average cost of $14.23 per share, for a total transaction of $71,150.00. Following the completion of the transaction, the director now owns 5,000 shares of the company’s stock, valued at $71,150. The disclosure for this purchase can be found here. Over the last three months, insiders sold 58,035 shares of company stock worth $1,297,612. 6.40% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Alps Advisors Inc. grew its position in OraSure Technologies by 0.3% during the second quarter. Alps Advisors Inc. now owns 43,257 shares of the medical instruments supplier’s stock valued at $747,000 after purchasing an additional 111 shares in the last quarter. Profund Advisors LLC grew its position in OraSure Technologies by 2.8% during the second quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock valued at $188,000 after purchasing an additional 293 shares in the last quarter. Timber Hill LLC grew its position in OraSure Technologies by 3.2% during the second quarter. Timber Hill LLC now owns 11,597 shares of the medical instruments supplier’s stock valued at $200,000 after purchasing an additional 363 shares in the last quarter. Arizona State Retirement System grew its position in OraSure Technologies by 3.4% during the second quarter. Arizona State Retirement System now owns 30,100 shares of the medical instruments supplier’s stock valued at $520,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Louisiana State Employees Retirement System grew its position in OraSure Technologies by 5.9% during the second quarter. Louisiana State Employees Retirement System now owns 23,500 shares of the medical instruments supplier’s stock valued at $406,000 after purchasing an additional 1,300 shares in the last quarter. 94.41% of the stock is currently owned by hedge funds and other institutional investors.

OraSure Technologies (NASDAQ OSUR) opened at $16.38 on Friday. OraSure Technologies has a 1 year low of $8.21 and a 1 year high of $23.01. The company has a market cap of $1,022.53, a P/E ratio of 32.42, a P/E/G ratio of 3.24 and a beta of 1.39.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.09 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.09. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The firm had revenue of $42.30 million for the quarter, compared to the consensus estimate of $40.87 million. During the same period in the previous year, the firm posted $0.11 earnings per share. The firm’s revenue was up 31.0% on a year-over-year basis. sell-side analysts predict that OraSure Technologies will post 0.42 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “OraSure Technologies Target of Unusually High Options Trading (OSUR)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/25/orasure-technologies-target-of-unusually-high-options-trading-osur.html.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Receive News & Stock Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related stocks with our FREE daily email newsletter.